“Four Diamonds allows us to pursue avenues that otherwise wouldn’t be funded—more risky approaches that the federal government or other agencies will not fund until there’s a substantial amount of preliminary data to support it. Four Diamonds is absolutely instrumental for testing novel ideas.”
NIH NIAMS RO1 AR063361
“RNA-binding protein CRD-BP in melanocyte biology”
NIH NCI R21 CA191550
“CRD-BP-mediated regulation of Wnt signaling in intestinal tumorigenesis”
PA Tobacco Settlement Fund
Precision Medicine for Melanoma Treatment
“Achilles’ heel in Melanoma – CRD-BP as a Potential Prognostic Marker and Therapeutic Target”
Career Development Award Xu, Y. (PI)
Spiegelman, V. (mentor)
Dr. Spiegelman’s research focuses on the understanding of molecular pathways and environmental factors that lead to development of human malignancies, and employment of newly acquired knowledge for eradication of cancer. His research focuses on the mechanisms that govern the turnover of short-lived mRNAs that encode important regulators of cell proliferation, death and differentiation and the implications of this turnover for tumor development. The mechanisms regulating mRNA degradation, its alterations in human cancers and its potential ability of therapeutic modality are of primary interest.
The following are publications of Dr. Spiegelman’s lab since 2012:
Ghoshal A., Rodrigues L. C. D. S., Gowda C., Elcheva I. A., Z., Abraham T., Spiegelman V.S. Extracellular vesicle-dependent effect of RNA-binding protein IGF2BP1 on melanoma metastasis, Oncogene, 2019, in press.
DiSano J.A., Huffnagle I., Gowda R., Spiegelman V.S., Robertson G.P., Pameijer C.R.. Loss of miR-155 upregulates WEE1 in metastatic melanoma, Melanoma Research, 2019 Apr;29(2):216-219.
Chamcheu J.C., Rady I., Chamcheu R.N., Siddique A.B., Bloch M.B., Banang Mbeumi S., Babatunde A.S., Uddin M.B., Noubissi F.K., Jurutka P.W., Liu Y.Y., Spiegelman V.S., Whitfield G.K., El Sayed K.A. Graviola (Annona muricata) Exerts Anti-Proliferative, Anti-Clonogenic and Pro-Apoptotic Effects in Human Non-Melanoma Skin Cancer UW-BCC1 and A431 Cells In Vitro: Involvement of Hedgehog Signaling. Int J Mol Sci. 2018, 19(6).
Kim T-W, Havighurst T., Kim KM., Albertini M., Xu Y.G., and Spiegelman V.S. Targeting insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in metastatic melanoma to increase efficacy of BRAFV600E inhibitors, Molecular Carcinogenesis, 2018, 57(5):678-683.
Poenitzsch Strong A.M., Berry S.M., Beebe D.J., and Spiegelman V.S.. miFAST: a novel, rapid miRNA-direct target mRNA capture and enrichment method for the characterization of miRNA direct targetomes. Molecular Carcinogenesis, 2018, 57(4):559-556.
Kim T-W., Havighurst T., Kim KM., Hebbring S.J., Ye Z., Aylward J., Keles S., Xu Y.G., and Spiegelman V. S. RNA-Binding Protein IGF2BP1 in Cutaneous Squamous Cell Carcinoma. Journal of Investigative Dermatology, 2017; 137(3):772-775.
Hamilton K.E., Chatterji P., Lundsmith E.T., Andres S.F., Giroux V., Hicks P.D., Noubissi F.K., Spiegelman V.S., and Rustgi AK. Loss of Stromal Imp1 Promotes a Tumorigenic Microenvironment in the Colon. Mol Cancer Res. 2015; 13(11):1478-86.
Fakhraldeen S.A., Clark R.J., Roopra A., Chin E.N., Huang W., Castorino J., Wisinski K.B., Kim T., Spiegelman V.S., and Alexander C.M. Two isoforms of the RNA binding protein, Coding Region Determinant-binding Protein (CRD-BP/IGF2BP1), are expressed in breast epithelium, and support clonogenic growth of breast tumor cells. J Biol Chem. 2015; 290(21):13386-400.
Goswami S., Tarapore R. S., Poenitzsch-Strong A.M., TeSlaa J. J., Grinblat Y., Setaluri V., and Spiegelman, V.S. MicroRNA-340-Mediated Degradation of Microphthalmia-Associated Transcription Factor (MITF) mRNA is Inhibited by Coding Region Determinant Binding Protein (CRD-BP). J Biol Chem. 2015; 290(1):384-95.
Poenitzsch-Strong A.M., Setaluri V., and Spiegelman, V.S. microRNA-340 as a modulator of RAS-RAF-MAPK signaling in melanoma. Arch Biochem Biophys, 2014, 563:118-24, 563:118-24.
Wu J., Salva K, Stutz N., Longley, B. J., Spiegelman, V.S., and Wood, G. S. Quantitative Gene Analysis of Methylation and Expression (Q-GAME) in Fresh or Fixed Cells and Tissues, Exp. Dermatology, 2014, 23(5):304-9
Noubissi F. K., Kim T-W., Kawahara T., Longley B. J., Aughenbaugh W.D., Berg E., Athar M., and Spiegelman V. S. Role of CRD-BP in the growth of human basal cell carcinoma cells. Journal of Investigative Dermatology, 2014, 134(6):1718-24.
Athar M., Li C., Kim A.L., Spiegelman V.S., Bickers D.R. Sonic Hedgehog signaling in Basal Cell Nevus Syndrome. Cancer Research, 2014; 74(18):4967-752014.
Wood, G. S. , Gunkel, J., Spiegelman, V.S., Snow, S., Vanness, E., Teng, J.M., and Xu Y. Non-melanoma skin cancer. In: Abeloff’s Clinical Oncology. Fifth edition. ELSEVIER, 2014.
Hamilton K.E., Noubissi F.K., Katti P.S.,. Hahn C.M, Davey S.R., Lundsmith E.T., Klein-Szanto A.J., Rhim A.D., Spiegelman V.S., Rustgi A.K. IMP1 promotes tumor growth, dissemination, and a tumor-initiating cell phenotype in colorectal cancer cell xenografts. Carcinogenesis 34(11):2647-54, 2013.
Tarapore R.S., Siddiqui I.A., Adhami V.M., Spiegelman V.S., Mukhtar H. The dietary terpene lupeol targets colorectal cancer cells with constitutively active Wnt/β-catenin signaling, Molecular Nutrition & Food Research, 57(11):1950-8, 2013.
Craig E.A., Weber J.D. and Spiegelman V. S. Involvement of the mRNA binding protein CRD-BP in the regulation of metastatic melanoma cell proliferation and invasion by hypoxia. Journal of Cell Science. 125(Pt 24):5950-4, 2012.
Schmit T.L., Nihal M., Ndiaye M.A., Setaluri V., Spiegelman V.S. and Ahmad N. Numb regulates stability and localization of the mitotic kinase PLK1 and is required for transit through mitosis. Cancer Research. 72(15):3864-72, 2012.
Craig E. and Spiegelman V. S. Inhibition of coding region determinant binding protein sensitizes melanoma cells to chemotherapeutic agents. Pigment Cell Melanoma Res. Jan;25(1):83-7, 2012.